10-Q: Krystal Biotech Soars on Strong VYJUVEK Sales, Profitability

Krystal Biotech reports significant revenue growth and net income for Q3 and nine months ended September 30, 2025, driven by strong VYJUVEK sales and a deferred tax asset release.

Summary

• Net income for the three months ended September 30, 2025, was $79.4 million, a 192% increase from $27.2 million in the same period of 2024.
• Net income for the nine months ended September 30, 2025, was $153.4 million, a 251% increase from $43.7 million in the same period of 2024.
• Product revenue, net, for Q3 2025 reached $97.8 million, up 17% from $83.8 million in Q3 2024.
• Product revenue, net, for the nine months ended September 30, 2025, was $282.0 million, a 41% increase from $199.4 million in the prior year period.
• Gross margin improved to 96% for Q3 2025, compared to 92% in Q3 2024.
• Income from operations increased by 84% to $41.4 million in Q3 2025 and by 380% to $117.0 million for the nine months ended September 30, 2025.
• The accumulated deficit was significantly reduced to $27.2 million as of September 30, 2025, from $180.7 million as of December 31, 2024.
• A $48.4 million valuation allowance on U.S. federal and certain state deferred tax assets was released in Q3 2025, contributing to a $31.4 million income tax benefit.
• Cash, cash equivalents, and short-term investments totaled $731.1 million as of September 30, 2025, deemed sufficient to fund operations for at least the next 12 months.
• VYJUVEK's FDA label was expanded in September 2025 to include DEB patients from birth and allow flexible administration by healthcare professionals, caregivers, or patients at home.
• VYJUVEK was commercially launched in Germany in August 2025, France in October 2025 (with early reimbursed access), and Japan in October 2025.
• The FDA granted platform technology designation to the engineered HSV-1 viral vector used in KB801 in October 2025.
• Positive interim efficacy data for inhaled KB707 in NSCLC showed a 36% objective response rate and 54% disease control rate in an evaluable cohort of 11 patients, with FDA feedback suggesting a single Phase 3 study may be sufficient for registration.

Sentiment

Score: 9

Explanation: The company demonstrated exceptional financial performance, significantly exceeding prior year results in revenue, net income, and operational income. The successful global commercialization of VYJUVEK, coupled with an impressive 96% gross margin, indicates strong market penetration and profitability. The substantial reduction in accumulated deficit and the release of a significant deferred tax asset valuation allowance underscore a robust financial turnaround. Furthermore, the company's pipeline shows promising advancements, including an FDA platform technology designation for a key vector and a potential streamlined registrational pathway for KB707 in NSCLC. While legal inquiries and ongoing European pricing negotiations present some uncertainties, the overall trajectory of commercial success, financial health, and pipeline progress strongly supports a highly positive outlook.

Positives

• Net income surged by 192% in Q3 2025 to $79.4 million and by 251% for the nine months to $153.4 million, demonstrating strong profitability.
• Product revenue, net, grew by 17% in Q3 2025 to $97.8 million and by 41% for the nine months to $282.0 million, driven by robust VYJUVEK sales.
• Gross margin improved significantly to 96% in Q3 2025, indicating efficient manufacturing and strong pricing power for VYJUVEK.
• Income from operations increased substantially by 84% in Q3 2025 and 380% for the nine months, reflecting enhanced operational leverage.
• The accumulated deficit was reduced from $180.7 million to $27.2 million, signaling a strong move towards sustained overall profitability.
• A $48.4 million valuation allowance on deferred tax assets was released, resulting in a $31.4 million income tax benefit in Q3 2025, reflecting increased confidence in future taxable earnings.
• Strong liquidity position with $731.1 million in cash, cash equivalents, and short-term investments, providing ample runway for planned operations for at least 12 months.
• VYJUVEK's FDA label was expanded to include DEB patients from birth and allow flexible administration, broadening market access and patient convenience.
• Successful commercial launches of VYJUVEK in Germany, France (with early reimbursed access), and Japan mark significant global market expansion.
• The FDA granted platform technology designation to the HSV-1 viral vector used in KB801, potentially streamlining future drug development and regulatory processes.
• Inhaled KB707 for NSCLC showed promising monotherapy activity (36% objective response rate, 54% disease control rate), and FDA feedback suggests a single Phase 3 study may be sufficient for registration, accelerating its path to market.
• KB803 (Ocular DEB) initiated a Phase 3 registrational study, building on positive compassionate use case observations of full corneal healing and visual acuity improvement.
• KB111 (Hailey-Hailey Disease) received FDA IND clearance, advancing a new candidate into clinical development.
• KB304 (Aesthetics) reported positive Phase 1 safety and efficacy results, progressing to a Phase 2 study.

Negatives

• Interest and other income, net, decreased by 10% in Q3 2025 and 5% for the nine months ended September 30, 2025, compared to the prior year periods.
• Selling, general and administrative expenses increased significantly by 31% in Q3 2025 and 28% for the nine months, driven by commercialization efforts and professional services, which could pressure margins if revenue growth slows.
• Research and development expenses increased by 8% for both the three and nine months, indicating continued high investment in the pipeline, which is typical but impacts current profitability.
• The company is subject to a U.S. Department of Justice inquiry regarding its sponsored genetic testing program and commercial practices for VYJUVEK, with an inability to estimate potential loss.
• A stockholder filed a derivative complaint alleging excessive non-employee director compensation from 2021-2024, seeking unspecified damages and corporate governance reforms.
• Pricing negotiations for VYJUVEK in Germany and France are ongoing and expected to continue until at least the second half of 2026, introducing uncertainty regarding revenue realization in these key European markets.
• Enrollment in OPAL-1 (intratumoral KB707) has been paused, indicating a reprioritization or potential setback for that specific formulation.

Risks

• Operating profitability is dependent upon the continued successful commercialization of VYJUVEK and successful development, approval, and commercialization of product candidates.
• Subject to risks common to the biotechnology industry, including failure of product candidates in clinical and preclinical studies, development of competing products, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to commercialize product candidates.
• Expects to incur significant costs to further its pipeline and expand commercialization capabilities globally.
• Future revenue will fluctuate due to uncertain timing and amount of product sales and variable consideration (discounts, returns, copay assistance, rebates).
• Inability to determine with certainty the duration, costs, and timing of clinical trials, potentially leading to actual costs exceeding expected costs.
• Potential for material dilution of existing stockholders' ownership interests if additional capital is raised through equity sales.
• Debt financing, if available, could result in increased fixed payment obligations and restrictive covenants.
• Failure to raise capital when needed could force delays, scaling back, or discontinuation of development/commercialization, or unfavorable collaboration terms.
• Reliance on third-party Contract Manufacturing Organizations (CMOs) for some manufacturing activities and Contract Research Organizations (CROs) for clinical development activities.
• Exposure to costly litigation and potential adverse impact on operations, cash flows, and financial position from legal proceedings, including the U.S. Department of Justice inquiry and the stockholder derivative lawsuit.
• Insurance carriers may deny coverage, be inadequately capitalized, or policy limits may be insufficient for legal claims.
• Market risk from investments in financial instruments due to changes in prevailing interest rates.
• Foreign exchange rate risk from operations in Europe and Japan (Swiss Francs, Euros, Japanese Yen).
• Inability to provide absolute assurance that future investments will not be subject to adverse changes in market value.

Future Outlook

The company expects research and development expenses to increase as it continues manufacturing preclinical and clinical materials, manages clinical trials, seeks regulatory approvals, and expands its product portfolio. Selling, general and administrative expenses are also anticipated to rise due to commercialization efforts, hiring additional personnel, and increased costs for insurance, consultants, lawyers, and accountants. Management believes its current cash, cash equivalents, and short-term investments of $731.1 million are sufficient to fund planned operations for at least the next 12 months. Pricing negotiations for VYJUVEK in Germany and France are expected to continue until at least the second half of 2026. The company anticipates reporting safety and CFTR delivery data from the final cohort of CORAL-1 (KB407) by year-end, interim safety and SERPINA1 delivery data from SERPENTINE-1 (KB408) in H1 2026, and completing enrollment in the IOLITE (KB803) study by year-end. A Phase 2 study for KB304 is expected to initiate in H1 2026, and HHD patients are expected to be dosed in a clinical study for KB111 in H1 2026. Interim efficacy data from KYANITE-1 (KB707) and potential registrational study plans are expected in H2 2026, and the specialty distributor network is expected to expand in 2026.

Management Comments

• Our operating profitability is dependent upon the continued successful commercialization of VYJUVEK, our U.S. Food and Drug Administration (FDA), European Commission (EC), and Japans Ministry of Health, Labour, and Welfare (MHLW) approved product, as well as successful development, approval and commercialization of our product candidates.
• Management intends to fund future operations through its on hand cash and cash equivalents and revenue generated from the sale of VYJUVEK, and may also seek additional capital through arrangements with strategic partners, the sale of equity, debt financings or other sources.
• We believe that our cash, cash equivalents and short-term investments of approximately $731.1 million as of September 30, 2025 will be sufficient to allow us to fund our planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q.
• We expect our future revenue to fluctuate from quarter to quarter for many reasons, including the uncertain timing and amount of any product sales.
• We have based our projections of operating capital requirements on assumptions that may prove to be incorrect, and we may use all of our available capital resources sooner than we expect.
• Because of the numerous risks and uncertainties associated with research, development, manufacturing and commercialization of genetic medicines, we are unable to estimate the exact amount of our operating capital requirements.
• Forward-looking statements represent our managements beliefs and assumptions only as of the date of filing this Quarterly Report on Form 10-Q with the SEC. Except as required by law, we assume no obligation to update these forward-looking statements publicly as a result of subsequent events, developments or otherwise, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Industry Context

Krystal Biotech operates in the highly competitive and rapidly evolving genetic medicines and biotechnology industry. The company is positioned as a fully integrated, commercial-stage, global biotechnology firm, leveraging its patented HSV-1 gene therapy platform. VYJUVEK's status as the first redosable gene therapy and the first and only corrective medicine approved by the FDA for both recessive and dominant subtypes of DEB establishes a significant competitive advantage and market leadership in this rare disease space. The company's strategic expansion into European and Japanese markets for VYJUVEK aligns with broader industry trends of globalizing successful rare disease therapies. The FDA's platform technology designation for the HSV-1 vector used in KB801 is a notable achievement, potentially offering efficiencies in drug development and regulatory processes, akin to the benefits seen with other established platform technologies in biotech. Krystal Biotech's diverse pipeline, addressing other rare diseases (Cystic Fibrosis, Alpha-1 Antitrypsin Deficiency, Neurotrophic Keratitis, Hailey-Hailey Disease) and solid tumors, demonstrates a broad therapeutic focus within the growing gene therapy sector. The subsidiary Jeune Aesthetics also represents a unique diversification strategy, applying the gene therapy platform to aesthetic medicine.

Comparison to Industry Standards

• VYJUVEK is the first and only corrective medicine approved by the FDA for both recessive and dominant subtypes of Dystrophic Epidermolysis Bullosa (DEB), setting a new standard for treatment in this rare disease, distinguishing it from supportive care options.
• VYJUVEK is also the first ever redosable gene therapy, a significant advancement compared to many gene therapies that are single-dose treatments, offering greater flexibility and potential for sustained efficacy.
• The gross margin of 96% in Q3 2025 and 94% for the nine months 2025 is exceptionally high, significantly exceeding typical pharmaceutical industry gross margins, which often range from 70-90%. This indicates strong pricing power and/or highly efficient manufacturing for a specialized product.
• The FDA's platform technology designation for the HSV-1 viral vector used in KB801 is a substantial regulatory achievement. This designation is comparable to the recognition of other advanced platforms like mRNA (e.g., Moderna, BioNTech) or CAR-T cell therapies (e.g., Novartis, Gilead), potentially streamlining future drug development and regulatory processes by leveraging manufacturing and nonclinical safety data from approved products like VYJUVEK.
• The Prix Galien Italia award for VYJUVEK recognizes excellence in scientific innovation, placing it among leading advanced therapy medicinal products in the industry, similar to how other groundbreaking therapies are recognized globally.

Corporate Governance

Legal Proceedings

• U.S. Department of Justice Inquiry: Received subpoenas requesting documents regarding its sponsored genetic testing program relating to VYJUVEK and commercial practices. The company is cooperating, but it is not possible to estimate the amount or range of possible loss, and unfavorable outcomes could materially impact results of operations.
• Stockholder Derivative Complaint: Filed on September 18, 2025, alleging breach of fiduciary duty, unjust enrichment, and waste of corporate assets based on allegedly excessive non-employee director compensation from 2021 through 2024. Seeks unspecified damages, restitution, and corporate governance reforms. The company cannot reasonably estimate the likelihood of an unfavorable outcome or potential loss.
• PeriphaGen Litigation Settlement: The final payment of the $75.0 million settlement was completed during the three months ended March 31, 2025. No further litigation settlement expense was recorded in the current reporting periods.

Stakeholder Impact

• Shareholders: Positive financial results, strong liquidity, and pipeline advancements could enhance shareholder value. However, potential future equity raises could lead to dilution, and ongoing legal proceedings introduce uncertainty.
• Patients (DEB): Expanded VYJUVEK label and global commercial launches increase access to the first corrective gene therapy for Dystrophic Epidermolysis Bullosa, improving treatment options.
• Employees: Continued investment in R&D and SG&A suggests ongoing growth and opportunities, with stock-based compensation remaining a significant component of remuneration.
• Customers (Healthcare Professionals, Caregivers): The expanded VYJUVEK label offers greater flexibility for administration, potentially easing treatment burden.
• Regulatory Authorities: Ongoing cooperation with the DOJ inquiry and the FDA's platform technology designation for KB801 vector highlight continued engagement and regulatory achievements.
• Suppliers/CMOs/CROs: Continued reliance on third-party organizations for manufacturing and clinical development indicates ongoing business relationships and demand for their services.

Next Steps

• Continue commercialization of VYJUVEK in the United States, Europe, and Japan.
• Continue pricing negotiations for VYJUVEK in Germany and France, expected until at least the second half of 2026.
• Prepare regulatory filings for VYJUVEK in the United Kingdom and Switzerland.
• Initiate pricing discussions with relevant authorities in other key Western European markets for VYJUVEK.
• Expand the specialty distributor network for VYJUVEK in 2026.
• Report safety and CFTR delivery data from the third and final cohort of CORAL-1 (KB407) before year-end.
• Report interim safety and SERPINA1 delivery data from the repeat dose Cohort 2B of SERPENTINE-1 (KB408) in the first half of 2026.
• Complete enrollment in the IOLITE (KB803) study by year-end.
• Initiate Phase 2 study for KB304 in the first half of 2026.
• Dose Hailey-Hailey Disease (HHD) patients in a clinical study for KB111 in the first half of 2026.
• Report interim efficacy data from KYANITE-1 (KB707) and potential registrational study plans in the second half of 2026.
• Evaluate aesthetic indications most suitable for advanced clinical development of KB301.
• Continue to evaluate all available evidence each reporting period and may adjust the valuation allowance for deferred tax assets in future periods.

Key Dates

Recommendation

Krystal Biotech has demonstrated exceptional financial performance, significantly exceeding prior year results in revenue, net income, and operational income. The successful global commercialization of VYJUVEK, coupled with an impressive 96% gross margin, indicates strong market penetration and profitability. The substantial reduction in accumulated deficit and the release of a significant deferred tax asset valuation allowance underscore a robust financial turnaround. Furthermore, the company's pipeline shows promising advancements, including an FDA platform technology designation for a key vector and a potential streamlined registrational pathway for KB707 in NSCLC. While legal inquiries and ongoing European pricing negotiations present some uncertainties, the overall trajectory of commercial success, financial health, and pipeline progress strongly supports a 'Strong Buy' recommendation for long-term investors.

Keywords

Gene therapy, Biotechnology, VYJUVEK, Epidermolysis Bullosa (DEB), Rare disease, Genetic medicine, Clinical trials, FDA approval, Commercialization, Orphan drug, Dermatology, Ophthalmology, Oncology, Cystic Fibrosis (CF), Alpha-1 Antitrypsin Deficiency (AATD), Neurotrophic Keratitis (NK), Hailey-Hailey Disease (HHD), Non-small cell lung cancer (NSCLC), Aesthetic medicine, HSV-1 vector, Krystal Biotech